Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21799578 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL8553937 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL9322416 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL5839696 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL491616 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL7230416 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL21799504 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL21799790 | 1.00 | HRH3 (0.75) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| SCHEMBL10480715 | 0.98 | HRH3 (0.71) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT | |
| Hydrazine SCHEMBL8558416 | 0.98 | HRH3 (0.71) | HRH3SMN1; SMN2KEAP1SIGMAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4457258-A1 | POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM | ARKEMA FRANCE (FR) | 2024-11-06 | — | — | EP | claimed |
| CN-118488982-A | Polyol catalyst for two-component polyurethane systems | 阿科玛法国公司 | 2024-08-13 | — | — | CN | claimed |
| WO-2023126199-A1 | POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM | ARKEMA FRANCE (FR) | 2023-07-06 | — | — | WO | claimed |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SCHWARTZ JEAN-CHARLES (FR) | 2011-11-17 | — | — | US | claimed |
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-26 | — | — | US | claimed |
| EP-1863486-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-12 | — | — | EP | claimed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | claimed |
| WO-2006103537-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-10-05 | — | — | WO | claimed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1707203-A1 | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1606019-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | The University Court of The University of Aberdeen (GB) | 2005-12-21 | — | — | EP | claimed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | claimed |
| WO-2004078261-A1 | CANNABINOID RECEPTOR INVERSE AGONISTS AND NEUTRAL ANTAGONISTS AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE DISORDERS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2004-09-16 | — | — | WO | claimed |
| EP-0614664-B2 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | claimed |
| EP-0982300-A2 | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications | SOCIETE CIVILE BIOPROJET (FR) | 2000-03-01 | — | — | EP | claimed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | claimed |
| EP-4457258-A1 | POLYOL CATALYST FOR A TWO-COMPONENT POLYURETHANE SYSTEM | ARKEMA FRANCE (FR) | 2024-11-06 | — | — | EP | disclosed |
| WO-1993018017-A1 | CATALYTIC REFORMING OF CYCLIC ALKYLENEAMINES | THE DOW CHEMICAL COMPANY (US) | 1993-09-16 | — | — | WO | disclosed |
| CN-1073173-A | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1993-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HRH3 1/4885SMN1; SMN2 3856/4885KEAP1 2329/4885 |
| US-20110281844-A1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | HRH3, HRH4, HRH2 | HRH3 1/4885SMN1; SMN2 3925/4885KEAP1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.